Overview

Valproic AcId for Traumatic BRAin INjury Trial

Status:
NOT_YET_RECRUITING
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI). Patients with moderate to severe TBI will randomly receive either: 1. Standard of care treatment and normal saline 2. Standard of care treatment and one dose of valproic acid (VPA) at a lower dose or a higher dose
Phase:
PHASE2
Details
Lead Sponsor:
Northwestern University
Collaborator:
United States Department of Defense
Treatments:
Saline Solution
Valproic Acid